slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 88,501-88,530
Pages 3,225
Rows per page 30
Component
88,501-88,530 of 96,741
13
The slide uses a Land & Expand framework to categorize key business performance indicators.Doximity | Investor Presentation Deck | 18 slides · Doximity
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
08
The chart displays 69 projects as individual data points, with horizontal reference lines for average ROI and break-even point.Embracer Group | Results Presentation Deck | 25 slides · Embracer Group
Conference presentation Investor relations 1 hit
13
The slide distinguishes between historical data (dark purple) and forecast data (red).Embracer Group | Results Presentation Deck | 25 slides · Embracer Group
Conference presentation Investor relations Beat · Problem1 hit
22
Part of a Q1 update presentation for Embracer Group.Embracer Group | Results Presentation Deck | 25 slides · Embracer Group
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
04
Enochian Biosciences | Results Presentation Deck | 43 slidesEnochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations 1 hit
07
The slide uses a flow-based diagram to show how pipeline assets are developed and then monetized through various business strategies.Enochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations 1 hit
21
Enochian Biosciences | Results Presentation Deck | 43 slidesEnochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
23
Enochian Biosciences | Results Presentation Deck | 43 slidesEnochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
29
The chart shows a significant drop in viral load starting around day 14, stabilizing at a low level from day 145 onwards.Enochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
30
Enochian Biosciences | Results Presentation Deck | 43 slidesEnochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
06
Includes footnote regarding currency exchange rate for the option exercise payment.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a visual comparison to frame the problem of 'too narrow' vs 'too broad' inhibition.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Problem1 hit
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Problem1 hit
12
The slide highlights the structural commonality of the γC receptor across multiple cytokines, positioning it as a therapeutic target.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
17
The slide uses a structured layout to compare four distinct market segments (Cutaneous T cell Lymphoma, Alopecia Areata, Vitiligo, Atopic Dermatitis) with specific patient counts and clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Market Size1 hit
18
The slide uses a four-column structure to explain the target, the molecule type, preclinical results, and clinical results.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Market Size1 hit
19
Western blot data visualization comparing pathway activation (pSTAT, pERK, pPI3K) under different treatment conditions.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
20
Includes comparative data against Mogamulizumab (MAVORIC trial) and visual evidence of skin improvement.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
22
The slide uses a circular process diagram to show the feedback loop of immune cell activation and hair follicle damage.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
23
Includes photographic evidence of hair regrowth over 21 days and a bar chart showing fold reduction of NKG2D marker.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
25
Includes a blackbox warning text block as a competitive/safety barrier context.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
The slide outlines a clinical trial methodology and the strategic positioning of the drug candidate.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
Uses a contrast-based framing (750k patients vs 0 drugs) to establish market opportunity.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
29
The slide uses a four-column structure to explain the biological rationale, molecular nature, mechanism of action, and clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
30
Includes a heatmap showing gene expression profiles under different cytokine conditions.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a circular process diagram to show the mechanism of action and a bar chart to show efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
32
The slide uses a process-like flow to highlight the specific mechanism of action (IL-15/IL-21) compared to other approaches.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Why Now1 hit
37
Includes a disclaimer regarding the Form 10-Q and a footnote about debt facility prepayment.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
38
The slide uses a table-like structure to present clinical trial milestones and financial runway.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
08
The slide uses a biological process diagram to map drug assets to specific protein targets.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit